143 related articles for article (PubMed ID: 38666427)
1. Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity.
Han J; Kim S; Hwang YH; Kim SA; Lee Y; Kim J; Cho S; Woo J; Jeong C; Kwon M; Nam GH; Kim IS
Adv Sci (Weinh); 2024 Apr; ():e2308662. PubMed ID: 38666427
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy.
Prakash A; Gates T; Zhao X; Wangmo D; Subramanian S
Pharmacol Ther; 2023 Jan; 241():108332. PubMed ID: 36526013
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models.
Droste M; Thakur BK; Eliceiri BP
Front Immunol; 2020; 11():606859. PubMed ID: 33391275
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer.
Gates TJ; Wangmo D; Zhao X; Subramanian S
Mol Ther Oncolytics; 2023 Dec; 31():100727. PubMed ID: 37822487
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer.
Gates TJ; Wangmo D; Zhao X; Subramanian S
bioRxiv; 2023 Apr; ():. PubMed ID: 37131597
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulatory role of tumor-derived extracellular vesicles in colorectal cancer.
Manning S; Danielson KM
Immunol Cell Biol; 2018 Mar; ():. PubMed ID: 29575270
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Derived Extracellular Vesicles: Modulation of Cellular Functional Dynamics in Tumor Microenvironment and Its Clinical Implications.
Santos NL; Bustos SO; Bhatt D; Chammas R; Andrade LNS
Front Cell Dev Biol; 2021; 9():737449. PubMed ID: 34532325
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles.
Yu L; Zeng X; Hu X; Wen Q; Chen P
Colloids Surf B Biointerfaces; 2024 Feb; 234():113704. PubMed ID: 38113751
[TBL] [Abstract][Full Text] [Related]
9. Development of CD40L-modified tumor small extracellular vesicles for effective induction of antitumor immune response.
Liu W; Takahashi Y; Morishita M; Nishikawa M; Takakura Y
Nanomedicine (Lond); 2020 Jul; 15(17):1641-1652. PubMed ID: 32664826
[No Abstract] [Full Text] [Related]
10. Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy.
Yang A; Bai Y; Dong X; Ma T; Zhu D; Mei L; Lv F
Acta Biomater; 2021 Oct; 133():257-267. PubMed ID: 34407475
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived extracellular vesicles in breast cancer: From bench to bedside.
Wang HX; Gires O
Cancer Lett; 2019 Sep; 460():54-64. PubMed ID: 31233837
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
13. CD44 and Tumor-Derived Extracellular Vesicles (TEVs). Possible Gateway to Cancer Metastasis.
Szatanek R; Baj-Krzyworzeka M
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540535
[TBL] [Abstract][Full Text] [Related]
14. Molecular Determinants Involved in the Docking and Uptake of Tumor-Derived Extracellular Vesicles: Implications in Cancer.
Clares-Pedrero I; Rocha-Mulero A; Palma-Cobo M; Cardeñes B; Yáñez-Mó M; Cabañas C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542421
[TBL] [Abstract][Full Text] [Related]
15. Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination.
He T; Shi Y; Kou X; Shen M; Liang X; Li X; Wu R; You Y; Wu Q; Gong C
Biomaterials; 2023 Oct; 301():122218. PubMed ID: 37393695
[TBL] [Abstract][Full Text] [Related]
16. Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response: Role of mTOR/G-CSF pathway.
Koni M; Lopatina T; Grange C; Sarcinella A; Cedrino M; Bruno S; Buffolo F; Femminò S; Camussi G; Brizzi MF
Pharmacol Res; 2023 Sep; 195():106871. PubMed ID: 37506784
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic Extracellular Vesicles Derived from Endoplasmic Reticulum-Stressed Tumor Cells: Implications as the Therapeutic Cancer Vaccine.
Han KH; Kim CH; Kim SH; Lee CH; Park M; Bui VD; Duong VH; Kwon S; Ha M; Kang H; Park JH
ACS Nano; 2024 Jan; 18(1):199-209. PubMed ID: 38109681
[TBL] [Abstract][Full Text] [Related]
18. Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.
Ortiz-Bonilla CJ; Uccello TP; Gerber SA; Lord EM; Messing EM; Lee YF
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328324
[TBL] [Abstract][Full Text] [Related]
19. The capture of extracellular vesicles endogenously released by xenotransplanted tumours induces an inflammatory reaction in the premetastatic niche.
Blavier L; Nakata R; Neviani P; Sharma K; Shimada H; Benedicto A; Matei I; Lyden D; DeClerck YA
J Extracell Vesicles; 2023 May; 12(5):e12326. PubMed ID: 37194998
[TBL] [Abstract][Full Text] [Related]
20. Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents.
Bose RJC; Uday Kumar S; Zeng Y; Afjei R; Robinson E; Lau K; Bermudez A; Habte F; Pitteri SJ; Sinclair R; Willmann JK; Massoud TF; Gambhir SS; Paulmurugan R
ACS Nano; 2018 Nov; 12(11):10817-10832. PubMed ID: 30346694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
